Scancell (LON:SCLP) Trading Down 3.2% - Here's Why

Key Points

• Scancell Holdings plc (LON:SCLP) shares fell by 3.2% on Tuesday to GBX 9.69 ($0.13), with trading volume increasing by 44% from the average session.
• Insider Martin Diggle purchased 4,400,000 shares at an average cost of GBX 10, totaling £440,000, indicating confidence from company insiders.
• Scancell is a clinical stage immunotherapy biotech firm focusing on developing treatments for significant unmet cancer needs, including 'off-the-shelf' vaccines and monoclonal antibodies.

Scancell Holdings plc (LON:SCLP - Get Free Report) shares fell 3.2% on Tuesday . The company traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). 1,336,894 shares traded hands during trading, an increase of 44% from the average session volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Stock Down 1.4%

The business's fifty day moving average is GBX 10.15 and its two-hundred day moving average is GBX 9.63. The company has a market cap of £92.09 million, a P/E ratio of -426.63 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.

Insider Activity at Scancell

In other news, insider Martin Diggle acquired 102,236 shares of Scancell stock in a transaction that occurred on Thursday, August 7th. The stock was purchased at an average price of GBX 11 per share, for a total transaction of £11,245.96. Corporate insiders own 15.15% of the company's stock.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.